Watch for the New Osteoporosis Med, Romosozumab (Evenity)
September 2019
You'll see some postmenopausal women admitted on the new osteoporosis med romosozumab (Evenity, ee-VEN-ih-tee).
Romosozumab is an injectable monoclonal antibody that blocks sclerostin, a protein involved in bone metabolism. This leads to increased bone growth AND decreased bone breakdown.
Other osteoporosis meds do one or the other.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote